Evidence map›Paper›PMID 33216156›Full record

ArticleClinical neuroradiology2021

Initial Experience with Surpass Evolve Flow Diverter in the Treatment of Intracranial Aneurysms.

V Maus, W Weber, A Berlis, C Maurer, S Fischer

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical neuroradiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

V MausDepartment of Diagnostic and Interventional Neuroradiology and Nuclear Medicine, Ruhr University, Knappschaftskrankenhaus Bochum, In der Schornau 23-25, 44892, Bochum, Germany. volker.maus@kk-bochum.de.ORCID http://orcid.org/0000-0001-5097-2631
W WeberDepartment of Diagnostic and Interventional Neuroradiology and Nuclear Medicine, Ruhr University, Knappschaftskrankenhaus Bochum, In der Schornau 23-25, 44892, Bochum, Germany.
A BerlisDepartment of Diagnostic and Interventional Neuroradiology, University Hospital Augsburg, Augsburg, Germany.
C MaurerDepartment of Diagnostic and Interventional Neuroradiology, University Hospital Augsburg, Augsburg, Germany.
S FischerDepartment of Diagnostic and Interventional Neuroradiology and Nuclear Medicine, Ruhr University, Knappschaftskrankenhaus Bochum, In der Schornau 23-25, 44892, Bochum, Germany.
Universitätsklinikum Knappschaftskrankenhaus Bochum · DEUniversity Hospital Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe principle of flow diversion has revolutionized the treatment of brain aneurysms. In this study, we report our experience of the new Surpass Evolve (SE) flow diverter in the treatment of intracranial aneurysms. MATERIAL AND

methodsPatients were treated with the SE as first-line therapy between May 2019 and June 2020 at 2 experienced institutions. Inclusion criteria were wide-necked, blister-like, or fusiform/dissecting aneurysms in the anterior and posterior circulation. Primary endpoint was technical success defined as favorable navigation to the target vessel and successful deployment of the SE. Secondary endpoints were favorable aneurysm occlusion defined as O'Kelly Marotta (OKM) scale C1-3 + D on follow-up, procedure-related complications and retreatment.

resultsA total of 46 aneurysms in 42 patients were treated with 57 SE flow diverters. Median aneurysm size was 6.6 mm (IQR 4.0-12.2 mm) with a median neck width of 4 mm (IQR 2.2-5.4 mm). On admission, 6 (13%) aneurysms were ruptured and 41 (89%) were located in the anterior circulation. The primary endpoint was reached in 96%. Median follow-up was 116 days (IQR 92-134 days) and available for 36/46 (78%) aneurysms. Favorable aneurysm occlusion was seen in 31/36 (86%) aneurysms and 27/36 (75%) were occluded completely. Parent artery occlusion appeared in 3 (3%) patients on follow-up and 2 aneurysms (6%) required additional treatment due to insufficient closure.

conclusionThe new SE flow diverter is safe and seems to be effective with promising occlusion rates at short-term follow-up.

Indexed as

Endovascular ProceduresIntracranial AneurysmHumansRetrospective StudiesStentsTreatment OutcomeAneurysm occlusionEndovascular treatmentFlow diversionInterventional neuroradiologyIntracranial stenting

Identifiers

PMID33216156
OpenAlexW3098691045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.